Yucca Health Review: It Answers the FDA Question Better Than Anyone — Then Asks You to Prepay $750 With All Sales Final

What Is Yucca Health?

Yucca Health trades as Brand Merchants Network LLC, doing business as Yucca Health, from 9350 Wilshire Blvd, Suite 203, Beverly Hills, California. It sells compounded semaglutide and tirzepatide for weight management, plus NAD+ for 'longevity' and sermorelin for muscle recovery, with a peptides line advertised as coming soon. The site operates in English and Spanish, which is genuinely uncommon in this market and a real access advantage for Spanish-speaking patients.

The single best thing about it is the honesty on regulatory status. Its FAQ asks 'Are these medications FDA-approved?' and answers: 'No. Yucca provides compounded medications containing the same active pharmaceutical ingredients (APIs) as brand-name drugs. Compounded medications are prepared by licensed U.S. pharmacies, are not FDA-approved, and do not undergo FDA review for safety, effectiveness, or manufacturing quality.' That is the clearest, least evasive answer to this question we have encountered across more than fifty provider reviews. Most competitors qualify it, soften it, or make you find it.

Pricing is published too, in the same FAQ, which is more than several of its rivals manage: semaglutide from $125 a month on a six-month plan totalling $750, or $146 month-to-month; tirzepatide from $225 on six months totalling $1,350, or $258 month-to-month. The gap between the prepaid and monthly rate is around 15%, which is a fair discount rather than the doubling some providers use to push you onto long commitments.

It names its clinicians — Dr. Michael Wasef, MD and Dr. Andrew Sakla, DO, both board-certified in internal medicine — and publishes a full set of policy documents including terms, privacy, refund, shipping, medical safety information, consent to telehealth and a physician code of conduct. On the paperwork, this is a more complete operation than most.

What sits awkwardly alongside all of that is the marketing, and a question about scale that we cannot resolve and think you should ask.

Plans & What They Actually Cost

These figures come from Yucca's own FAQ, checked on 7 August 2026, and are unusually specific for this market — total plan cost is stated, not just a monthly headline. Note two frictions. The site says elsewhere that 'pricing is shared after intake once eligibility is confirmed', which contradicts the FAQ that publishes it; the FAQ numbers are the ones we would work from. And a BBB complainant describes signing up after seeing tirzepatide 'advertised as as low as $146/month' and expecting 'pricing to be close to the advertised amount' — $146 is the semaglutide monthly rate, not tirzepatide's, which is $258 month-to-month. Whether that was an advertising error or a misreading, confirm which drug your quoted price applies to before paying.

Compounded and Unapproved — What Yucca Tells You, and What It Doesn't

Everything Yucca sells is compounded, and it says so without flinching. Its answer to 'Are these medications FDA-approved?' is a flat 'No', followed by an accurate description: compounded medications contain the same active pharmaceutical ingredients as brand-name drugs, are prepared by licensed US pharmacies, are not FDA-approved, and do not undergo FDA review for safety, effectiveness or manufacturing quality. We have not seen a better version of that disclosure anywhere in this series.

Understand what it does and does not tell you. Same active ingredient is not the same product. The trials that produced the weight-loss figures you have read about — STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide — tested the branded, FDA-approved products, not compounded versions. Sterility, potency and consistency in a compounded injectable depend on the pharmacy that made it, and Yucca does not name the pharmacy. Ask which one fills your prescription and whether it is a 503A pharmacy or a 503B outsourcing facility.

NAD+ and sermorelin carry the same status with thinner justification. Neither has an FDA-approved product for the uses advertised here. Sermorelin's approved form, Geref, treated paediatric growth hormone deficiency and was discontinued in the US years ago. For NAD+, the FDA has publicly warned compounders that it is aware of food-grade NAD+ being used to make injectable products, cautioning that food-grade ingredients 'are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins'. That is an industry-wide warning rather than a finding about Yucca, but at $215 a month for a product with limited clinical evidence behind it, it is worth asking what grade of NAD+ is being used.

The eligibility language deserves a note. Yucca states you may qualify with a BMI of 30 or above, or 27 or above with a weight-related condition — which matches the FDA-approved indications for the branded products. It then adds that 'patients with BMI above 25 may also qualify depending on medical history, as determined by a licensed provider.' Prescribing below the approved thresholds is a clinical judgement a licensed provider is entitled to make, and it is not improper. But if you are between 25 and 27 with no weight-related condition, you are being offered a medication outside the population in which its benefits and risks were established, and that is worth a direct conversation with the prescriber rather than a checkbox.

The Consultation Process

Eligibility

• •Yucca states you may qualify with a BMI of 30 or above, or 27 or above with a weight-related condition such as type 2 diabetes, high blood pressure or high cholesterol — the standard thresholds. It adds that patients above BMI 25 may qualify depending on medical history, which goes beyond the approved indication; discuss that directly with the prescriber if it applies to you.
• •Available in all 50 states, in English and Spanish, to adults only.
• •GLP-1 medicines are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive.
• •Clinician judgement is needed for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst in the days after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •Rapid weight loss costs lean muscle as well as fat. Protein intake and resistance exercise matter, and are worth discussing with the care team.
• •Sermorelin should not be used by anyone with active cancer, and cancer survivors should decide with their oncologist. NAD+ and sermorelin are both compounded and unapproved, with limited evidence for the uses advertised.
• •If you stop a GLP-1, appetite generally returns and weight regain is common. A six-month prepaid plan is the beginning of a longer decision, not the whole of it.

Clinicians, Labs & Pharmacy

Shipping & Support Services

Free UPS 2-Day Air, which is faster than most and a genuine advantage for a temperature-sensitive product. Yucca publishes a separate shipping policy.

• •The clearest FDA-status disclosure we have found — a flat 'No' with an accurate explanation
• •Total plan cost published, not just a monthly headline
• •Only about a 15% gap between the six-month rate and month-to-month
• •Named, board-certified physicians
• •Full English and Spanish site
• •Free UPS 2-Day Air shipping
• •Identity verification before prescribing
• •Complete policy set including a physician code of conduct and telehealth consent
• •Provider review within a stated 24 hours
• •Terms state refunds are issued if a provider declines treatment

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Yucca Health May Be Best For

• •Spanish-speaking patients, who have very few good options in this market
• •Price-driven buyers who want tirzepatide near $225 a month and will commit six months
• •People who value being told plainly that compounded medication is not FDA-approved
• •Anyone who wants a named prescribing physician rather than an anonymous 'licensed provider'
• •Patients confident they will tolerate a GLP-1 — because the refund terms give you no way back if you don't

Limitations

• •Start with the refund terms, because they are where your money is at risk. 'All sales are final once an order has been shipped' is a defensible rule for a patient-specific compounded medication that genuinely cannot be resold. What is harder to defend is the absence of any pro-rata provision on a six-month prepayment. Roughly one in five people starting a GLP-1 finds the gastrointestinal side effects difficult, and some stop. If that is you in month two of a $1,350 tirzepatide plan, nothing in Yucca's published terms gives you your remaining months back. Choosing the month-to-month rate costs about 15% more and removes that exposure entirely — for a first course, that is money well spent.
• •The order of the checkout compounds it. Yucca's own six-step description has you paying at step two and receiving provider review at step four. Its terms of service do say refunds are issued 'if a provider does not approve treatment', which closes the loop — but its refund policy page, the document a customer would actually go looking for, does not mention declined patients at all. Two policy documents saying different things about the same scenario is the kind of gap that only matters when it matters. Get it confirmed in writing.
• •Then the question we cannot answer. The BBB lists Yucca Health with a start date of 24 March 2026 and declines to rate it on the grounds that it 'has been in business less than 6 months and does not have a sufficient track record'. Yucca's homepage simultaneously advertises '20,000+ Active patients', '100,000+ Prescriptions written across 50 states' and 1,206 Trustpilot reviews. Those two pictures are difficult to reconcile. There are innocent explanations — BBB start dates often reflect when a file was opened or when a particular legal entity was registered rather than when trading began, and the business operates under Brand Merchants Network LLC, which may have a longer history under other names. We are not alleging anything. But if the reassurance of scale is part of why you are choosing Yucca, ask them directly how long they have been operating and under what entity, because the public record does not support the homepage on its face.
• •The outcome marketing is the part we would change first. The homepage runs before-and-after photographs captioned with specific results — 'Lost 75 lbs in 10 Months', 'Lost 50 lbs in 6 Months' — alongside testimonials describing 100-pound losses, carrying only the line 'Individual patient experiences and results may vary.' The FTC's guidance on endorsements is that where results are not typical, a generic disclaimer of that kind is not adequate; advertisers should disclose the results consumers can generally expect. For context, the pivotal trial of branded semaglutide 2.4mg reported a mean weight change of about 14.9% over 68 weeks, and branded tirzepatide 15mg about 20.9% over 72 weeks — in trials of the approved products, not compounded ones. A 75-pound loss is achievable for some people; it is not what most should plan around.
• •Set against all this, the disclosure that matters most for safety is excellent, and we want to be clear about that. A company that answers 'Are these medications FDA-approved?' with 'No' and then explains what compounding actually means is doing something several better-established competitors will not. Add published total costs, named physicians, identity verification, a Spanish-language site and free two-day shipping, and there is a real operation here. Our reservations are about the money and the marketing, not the medicine.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Yucca Health gets the most important sentence right. Asked whether its medications are FDA-approved, it answers 'No', then explains accurately what compounded medication is and is not. Across more than fifty provider reviews in this series, that is the clearest version of that disclosure we have read, and it matters more than any feature list — it is the difference between a patient who understands what they are taking and one who doesn't. Publishing total plan costs rather than teaser monthlies, naming its physicians, verifying identity before prescribing, running the whole site in Spanish and shipping free by 2-Day Air all point the same direction.

Its pricing is competitive and, unusually, fair in structure. Semaglutide at $125 on six months or $146 month-to-month, and tirzepatide at $225 or $258, is about a 15% premium for staying flexible — a real choice, not the punitive gap some providers use to force a long commitment.

The money is where we would be careful. All sales are final once shipped, and nothing in the published terms gives you a pro-rata refund if you stop a six-month plan in month two. GLP-1 side effects stop a meaningful minority of people, and $1,350 of tirzepatide is a lot to have no way back from. You also pay before a provider has reviewed you — the terms say you are refunded if declined, but the refund policy page does not mention it, and two documents disagreeing is worth a written answer.

Then there is a gap between the marketing and the public record. The BBB lists this business as starting on 24 March 2026 and will not rate it for lack of track record; the homepage advertises 20,000 patients and 100,000 prescriptions. There are innocent explanations, and we are not alleging otherwise — but ask. And treat the before-and-after photographs as what they are: selected results, presented with a generic disclaimer that the FTC's own guidance says is not adequate where outcomes are atypical.

We rate Yucca Health 3.3 out of 5 — the best regulatory disclosure in this market, attached to prepayment terms that put the risk entirely on you and a marketing layer that oversells.

Buy it month-to-month rather than on the six-month plan, at least until you know you tolerate the medication. If you speak Spanish, the language support may outweigh everything else here. And if you want the lowest price with the least commitment, cheaper providers with longer records exist.

This review is informational only and is not medical advice. Compounded semaglutide, tirzepatide, NAD+ and sermorelin are not FDA-approved. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.